RE: Novartis buy FAP2286 from bankrupt Clovis12 Dec 2022 15:31
One can see that AVACTA has a suite of oncology assets which, once P1A results are out, far supersede the asset just sold by Clovis to Novartis. The overall deal to Clovis from Novartis is in excess of $580m far more than the current market capitalisation of AVACTA at c.$340m. In addition, AVACTA is fully funded having recently secured funds from one of the largest global hedge funds.
All of this in a market environment
In short, post AVA6000 results, AVACTA’s oncology assets are worth a sum that can’t really be estimated but it’s a very long way north of today’s valuation.